Day 2 #ASCO24 highlights: 1. #INAVO120: Inavolesib mPIK3CA HR+ LA/mBC 2. #postMONARCH: Abema + Fulvestrant after CDK4/6i in mBC 3. #EMERALD: Eribulin + HP HER2 mBC 4. Favorable/V Favorable mRCC 5. #DREAMM7: BVd 2L Myeloma #bcsm #lcsm #mmsm #OncTwitter ASCO 1/10

Final MAGNITUDE 📢 In mCRPC with BRCA mutations: Niraparib to Abiraterone = ⬇️ progression risk by 47% ⏳ rPFS: 19.5 vs 10.9 months 🧬 No benefit in non-HRR pts ✅ Confirmed the biomarker-driven benefit! European Urology Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Elena Castro AttardLab

KEYNOTE-991: Pembrolizumab + Enzalutamide + ADT vs Placebo + Enzalutamide + ADT in treatment-naive mHSPC. ⛔ Did not improve rPFS ⛔ No OS benefit ⛔ More toxicity Christian Gratzke Mehmet Ali Nahit Sendur Annals of Oncology OncoAlert Advanced Prostate Cancer Consensus Conference Uromigos annalsofoncology.org/article/S0923-…

Zoledronic acid vs. Denosumab in HR+/HER2- aBC with bone mets + CDK4/6i 🔍PSM/IPTW-adjusted retrospective study 🔹ZA prolonged time to 1st SRE vs. DMAB 🔹No difference in PFS or OS between groups 💥ZA might be preferred in this setting despite prior RCTs favoring DMAB?

Asterix and Ozempic 😅

Pembro/Axi vs. Nivo/Cabo as first-line therapy in mRCC patients. Out now another important experience by ARON project OncoDaily IKCC Kidney Cancer Kidney Cancer

HPV remains a topic that should never leave our agenda. Our article has been published; many thanks to Yüksel Ürün for the mentorship. Do not forget to get your children vaccinated against HPV. Let's protect the future. 🧬💉Viruses MDPI Ankara Üniversitesi mdpi.com/1999-4915/16/5…

The #ASCO25 #OncoAlertTOP10 Abstracts in #GUOncology These are some of our picks of TOP abstracts we look forward to be presented here in Chicago 🇺🇸 #ProstateCancer #BladderCancer #kidneyCancer ⭐Abs 4518 SURE-02: NEOADJUVANT SACITUZUMAB GOVITECAN PLUS PEMBROLIZUMAB, FOLLOWED

Day 1 #ASCO25 highlights: 1. Review on recent approvals 2. #BREAKWATER (update): BRAF+ mCRC 3. #CM8HW (update): MSI-H mCRC 4. #DYNAMIC: ctDNA in colon ca 5. #CAIRO6: periOP Rx in peritoneal mets #OncTwitter ASCO 1/6

Adjuvant Pembrolizumab vs Placebo in ccRCC—5-year update is here. 🟢 DFS: 58.5% vs 48.7% → +9.8% absolute benefit 🟢 OS: 86.1% vs 79.4% → +6.7% absolute benefit HR for OS: 0.66 | HR for DFS: 0.71 Benefit sustained beyond 5 years. A milestone for adjuvant immunotherapy in RCC.

🧬 IMmotion010 biomarker analysis: Tissue genomics + serum KIM-1 explored in adj atezolizumab for RCC 🔹 KIM-1 high + NMF6 (stromal/proliferative) → atezo benefit 🔹 Teff High + KIM-1 High → ↑ DFS with atezo 🔹 Progression = shift to NMF6 (↑ from 6% to 22%) 🔹 ↓ MHC-I

📢 #ASCO25 | CM 9ER Biomarker Analysis | 651 pts aRCC: Integrative analysis of circulating (e.g., early ctDNA clearance, peripheral immune subsets) & TME (CD8+ TIL density, PD‑L1 expression) determinants of response to NIVO+CABO. High baseline CD8+ TILs & ctDNA clearance

🌟Clear and compelling presentation by Renee Maria Saliby Gut-associated checkpoint as a prognostic biomarker in mRCC #ASCO25 OncoAlert🌟 🟢 Higher baseline sMAdCAM-1 levels associated with:  — ↑ PFS: 13.9 vs 8.4 mo → HR 0.75  — ↑ 18-mo OS rate: 84.2% vs 68.1% → HR 0.59 🟢

Day 2 #ASCO25 highlights: 1. #VERITAC2: Vepdegestrant HR+ mBC 2. #INAVO120 (update): Inavolisib HR+ mBC 3. #ASCENT04: Sacituzumab mTNBC 4. #CM577 (update): Adj Nivo GEJ/Gastric 5. #DESTINYGastric04: TDXd HER2+ GEJ/Gastric 6. #KN564 (update): Adj Pembro ccRCC ASCO 1/8

#ASCO25 Final results of IO-based combinations in mRCC are in! See below and subsequent posts for thoughts. Video discussing these data coming soon from OncoAlert...

Day 3 #ASCO25 highlights: 5 plenary studies 1. #ATOMIC: Adj Atezo in Stg III colon ca 2. #NIVOPOSTOP: Adj Nivo in high risk head & neck ca 3. #VERIFY: Rusfertide in PV 4. #SERENA6: Camizestrant in ESR1m breast Ca 5. #MATTERHORN: Peri/PostOP Durva in GEJ/Gastric ASCO 1/6

10-year follow up for pembro in MSI-H/dMMR advanced solid tumors 🔎KEYNOTE 16 👉10-yrs OS rate: 46% 👉Rare progression after 2 years 👉We need biomarker to identify (non-) responders 🧐 Great to see 10yr survival data for systemic therapies ESMO - Eur. Oncology

#ASCO2025 Poster presentation today: results of our Italian multicenter real-world PAMBRACA study. As first post-CDK4/6i line, PARPi associated with ⬆️rwPFS vs. ET or chemo in BRCA-associated HR+/HER2- aBC. No prior data on PARPi after CDK4/6i PD available before.

Day 4 #ASCO25 Highlights: 1. #DestinyBreast09: 1L TDXd Her2+ MBC 2. #SOFT/TEXT: Adj endo breast ca 3. #CM816: NeoAdj Nivo/chemo NSCLC 4. #NeoADAURA: NeoAdj Osi mEGFR NSCLC 5. #DeLLphi304: 2L Tarla SCLC 6. #IMForte: 1L maint Lurbi ES-SCLC 7. Timings for IO ASCO 1/8

In addition, we train AI in oncology for free by tweeting about scientific studies. (And if there’s a blue check, we even pay $8/month for it.) These overpriced publishing monopolies feel like music companies in the ’90s. Let's see when the 'academic' Spotify will start.